tachycardia. Propafenone had no effect on blood pressure, heart rate, PA interval, AV node refractoriness or rate of reentrant tachycardia. Propafenone significantly (p < 0.05) prolonged the AH, HV, QRS and ventricu-
Propafenone was administered during electrophysiologic testing to determine its efficacy and safety for terminating and preventing reinduction of paroxysmal supraventricular reentrant tachycardia. Four men and 10 women (mean age 50 years, range 28 to 69) were studied. Five patients had Wolff·Parkinson-White syndrome with orthodromic atrioventricular (AV) reentrant tachycardia, three had a concealed accessory pathway with AV reentrant tachycardia and six had tachycardia due to reentry within the AV node.
In the five patients with Wolff-Parkinson-White syndrome, propafenone terminated reentrant tachycardia in three (the tachycardia was reinducible in one) and had no effect in lWO. In the three patients with a concealed accessory pathway, propafenone terminated reentrant tachycardia in all three and prevented reinduction of the tachycardia in two. In the six patients with tachycardia due to reentry within the AV node, propafenone terminated and prevented reinduction of reentrant Propafenone, a class lC antiarrhythmic agent, should be effective in treating patients who have paroxysmal supraventricular reentrant tachycardia, because it affects conduction in the atrium, atrioventricular (AV) node, His-Purkinje system and ventricle and thus can prevent tachycardia by interfering with conduction in several places along the reentrant circuit (1) (2) (3) (4) (5) (6) . Previously, our group (7) demonstrated that propafenone is safe and effective for treating patients who have refractory complex ventricular ectopic rhythm.
We evaluated the effectiveness of intravenously admin-loatrial intervals and decreased the AV node Wenckebach rate.
Of the nine patients receiving long-term oral propafenone therapy, eight had a reduction of at least 90% in reentrant tachycardia during a mean follow·up period of 14.5 months (range 11 to 22); all eight patients had had noninducible reentrant tachycardia after intravenous propafenone. One patient had increased frequency of reentrant tachycardia; this patient had had inducible reentrant tachycardia after intravenous propafenone.
In conclusion, intravenously administered propafenone terminated reentrant tachycardia in 85% of patients and prevented reinduction in 71%, with no adverse hemodynamic effects.
(J Am Coli CardioI1987; 9:1364-8) istered propafenone in terminating supraventricular reentrant tachycardia during electrophysiologic testing. We assessed this agent's effect on the conduction properties of the AV conduction system and its ability to prevent reentrant tachycardia by programmed stimulation. We also reviewed the long-term results in patients who received oral propafenone therapy for control of reentrant tachycardia.
Methods
Study patients (Table 1 ). There were 14 patients (4 men and to women) with reentrant tachycardia refractory to previous antiarrhythmic therapy. The mean age of the patients was 50 years (range 28 to 69). Before electrophysiologic testing, six patients had no associated cardiac abnormality, five had Wolff-Parkinson-White syndrome, two had symptomatic coronary artery disease and one had mitral valve prolapse. Primary symptoms associated with the ar- rhythmia included palpitation q,Jtd weakness in seven patients. palpitation and light-headedness in four. angina in two and syncope in one. Previous treatment had been attempted with a mean of 3.5 (range I to 5) antiarrhythmic agents that were either ineffective in controlling the reentrant tachycardia or were poorly tolerated. The patients had been unsuccessfully treated with digoxin (12 patients). l3-adrenergic receptor blocking agents (I I patients), verapamil ( I I patients), quinidine (6 patients), procainamide (4 patients), disopyramide (4 patients) and amiodarone (l patient). Electrophysiologic testing. Electrophysiologic assessment was performed after obtaining informed consent, as reportedpreviously (8) . All antiarrhythmic drug therapy was discontinued at least five half-lives beforeelectrophysiologic study. The following variables were determined in the baseline state before the administration of propafenone or placebo: blood pressure, heart rate. PA interval, AH interval, HV interval, QRS duration, heart rate at which AV node Wenckebach conduction occurred. AV node effective refractory period, accessory pathway effective refractory period in the anterograde and retrograde directions, rate at which I: I conduction was maintained over the accessory pathway in the anterograde and retrograde directions and the mean heart rate and shortest RR interval between preexcited beats during atrial fibrillation in patients with Wolff-Parkinson-White syndrome. During reentrant tachycardia, the following variables were assessed before drug administration: cycle length. AH interval, HV interval and ven-PAROXYSMAL SUPRAVENTRICULAR REENTRANT TACHYCARDIA JACC Vol. 9. No.6
June 1987:1364--8 triculoatrial (VA) interval. The mechanism of the tachycardia was determined to be due to reentry within the AV node or utilization of a concealed or manifest accessory pathway using standard criteria (1) .
Study design. After determination of baseline variables, reentrant tachycardia was initiated and observed for at least 10 minutes in each patient. All patients were given a 10 minute infusion of either propafenone (2 mg/kg) or placebo, according to a double-blind, randomized, crossover coding system. A second infusion was given only if the reentrant tachycardia had not converted to sinus rhythm within 10 minutes of the first infusion. The reentrant tachycardia was terminated by programmed stimulation at the first sign of significant hemodynamic alteration or intolerable symptoms, or if 10 minutes had elapsed after the second infusion. After termination of reentrant tachycardia, the previously listed electrophysiologic variables were measured during sinus rhythm, after the sinus rate had stabilized. The induction of tachycardia was attempted using programmed stimulation, which consisted of incremental atrial pacing, the introduction of single and double premature atrial stimuli during sinus rhythm and atrial pacing, incremental ventricular pacing and the introduction of single ventricular stimuli during ventricular pacing. If reentrant tachycardia could be induced after the infusions, the electrophysiologic variables were again measured. Pacing threshold was two times threshold during baseline and after propafenone use. Blood samples were drawn for measurements of plasma propafenone at the end of each 10 minute infusion. After the study, all patients were closely observed by electrocardiographic (ECG) monitoring for 24 hours, and routine laboratory tests were obtained, including hemoglobin, hematocrit, leukocyte count, liver function tests and serum electrolytes, antinuclear antibody, creatinine, urea and creatine kinase. All patients tolerated the propafenone well, and complications were not observed. In addition, abnormalities on routine laboratory testing or 24 hour monitoring were not observed. Long-term treatment was determined by the referring physician and was carried out with propafenone in nine patients.
Statistics. Statistical analysis was performed using Student's two-tailed t test for paired data, and a probability (p) value of <0.05 was accepted as the limit of significance.
Results
There were five patients with Wolff-Parkinson-White syndrome and an accessory pathway capable of bidirectional conduction who had orthodromic AV reentrant tachycardia, three patients with an accessory pathway capable of only retrograde conduction (concealed accessory pathway) and AV reentrant tachycardia and six patients with AV node reentrant tachycardia.
Hemodynamic and conduction variables (Tables 2 and   3 ). Propafenone did not affect systolic or diastolic blood pressure, heart rate during sinus rhythm, PA interval or heart rate or AH interval during reentrant tachycardia. Propafenone significantly prolonged the following variables: rest AH interval, HV interval and QRS duration; HV interval during reentrant tachycardia; and VA interval during reentrant tachycardia. Propafenone significantly reduced the heart rate at which the Wenckebach conduction in the AV node occurred.
Effect of propafenone on reentrant tachycardia (Table 1). In five patients with Wolff-Parkinson-White syndrome and AV reentrant tachycardia, propafenone had no effect on the reentrant tachycardia in two patients, but terminated it in three; in one of these three the tachycardia could be reinduced. In all three patients with AV reentrant tachycardia utilizing a concealed accessory pathway, propafenone terminated the tachycardia. The tachycardia could no longer be induced in two of the patients and could be induced but was nonsustained in the other patient. In all six patients with reentry in the AV node, propafenone terminated the reentrant tachycardia, and in all six patients, the tachycardia could not be reinduced. (Table 3 ). In the five patients with Wolff-Parkinson-White syndrome, propafenone completely blocked conduction over the accessory pathway in two patients and decreased the rate of 1:1 conduction over the pathway during atrial pacing in three. Atrial fibrillation could not be induced in three of the patients after propafenone administration, and in the remaining two, the mean heart rate was slowed and the shortest RR interval between pre-excited beats was prolonged by propafenone ( Fig. 1 ). Plasma propafenone levels ( Table 1) . The mean plasma level of propafenone at the termination of tachycardia was 1,165 ng/ml (range 441 to 2,520). Patients who failed to respond to propafenonedid not have a significantly different plasma level from that of patients who did respond. Long-term follow-up (Table 1) . Nine patients received long-term oral propafenone therapy, with dosage ranging from 600 to 1, 200 mg daily in three or four divided doses (median dosage 300 mg 3 times daily). Eight patients had a reduction of :::::90% in symptomatic episodes of reentrant tachycardiaduring a mean follow-up period of 14.5 months (range lito 22). After intravenous propafenone therapy, reentrant tachycardia could not be induced during electrophysiologic testing in these eight patients. The ninth patient (Case 4) experienced an increase in the frequency of reentrant tachycardia episodes, and the use of propafenone was discontinued after 1 month. This patient's reentrant tachycardia was inducible after intravenous propafenone therapy during e1ectrophysiologic testing.
Effect of propafenone on anterograde accessory pathway conduction in Wolff-Parkinson-White Syndrome
The remaining five patients who did not receive propafenone had the following therapy: two patients had surgical division of their accessory pathway with no recurrence of reentranttachycardiaduring 10and 2I months, respectively; two patients received amiodarone therapy and had a reduction of :::::90% in the frequency of reentrant tachycardia during 21 months (both patients failed to respond to intravenous propafenone therapy during eiectrophysiologic testing); and the final patient underwent coronary artery bypass grafting for control of refractory angina, and her reentrant tachycardia was treated with digoxin and propranolol after she had refused oral propafenone therapy. This patient has had two episodes of reentrant tachycardia and required conversion of the arrhythmia in the emergency room.
Side effects. During long-term follow-up, the side effects associated with propafenone included headache in one patient and fatigue and nausea in one; the other six patients PAROXYSMAL SUPRAVENTRICULAR REENTRANT TACHYCARDIA JACC Vol. 9, No.6 June 1987:1364-8 did not experience side effects. None of the side effects required discontinuing propafenone use.
Discussion
Intravenously administered propafenone terminated reentrant tachycardia in 12 (85%) of 14 patients and prevented the reinduction of reentrant tachycardia in 10 (71%); there were no adverse hemodynamic effects or other evidence of toxicity. As has been documentedpreviously (7, 9) , the plasma level of propafenone varied widely and was not predictive of which patient would respond to intravenous propafenone therapy.
Effect of propafenone on conduction. Propafenone slowed conduction through the AV node (AH interval), through the His-Purkinje system (HV interval and QRS complex) and over the accessory pathway (VA interval). This result was consistent with propafenone's class IC effect (2, 10) . Propafenone slowed the rate of reentrant tachycardia from 172 ± 7 to 144 ± 6 beats/min just before termination, although this decrease was not statistically significant (p = 0.06).
Propafenone terminated reentrant tachycardia in all six patients with AV node reentrant tachycardia by slowing the conduction in the retrograde limb of the reentrant circuit (significant prolongation of the VA interval).
Propafenone for Wolff-Parkinson-White syndrome. Patients with Wolff-Parkinson-White syndrome are at risk for reentrant tachycardia and atrial fibrillation, during which they may experience rapid anterograde conduction over the accessory pathway, resulting in a rapid ventricular response and hemodynamic compromise (11) . As demonstrated in this and in previous studies (5), a class IC antiarrhythmic drug such as propafenone can terminate reentrant tachycardia in patients with Wolff-Parkinson-White syndrome by altering conduction in both the AV node and the accessory pathway and thus affecting both limbs of the reentrant circuit. This drug is also effective in controlling the ventricular response during atrial fibrillation by slowing the conduction in the anterograde direction over the accessory pathway.
In our study, the patients with Wolff-Parkinson-White syndrome had an accessory pathway with relatively long anterograde refractoriness and slow anterograde conduction. Patients with Wolff-Parkinson-White syndrome and an accessory pathway that demonstrates short refractoriness and rapid conduction may not be affected significantly by propafenone, as has been reported with procainamide, but this requires investigation (12) .
Long-term oral therapy with propafenone. Propafenone was effective and well tolerated in eight of the nine patients in whom it was used as long-term therapy. In these eight patients, reentrant tachycardia could not be induced after propafenone was administered, whereas in the patient in whom long-term propafenone therapy was not effective, sustained reentrant tachycardia was easily induced after propafenone was administered during the electrophysiologic study. This finding is consistent with previous data (13) indicating that the response to programmed stimulation during intravenous propafenone therapy in patients with reentrant tachycardia will predict their long-term response to oral propafenone therapy.
Conclusions. Intravenous propafenone therapy is effective for terminating reentrant tachycardia, and oral propafenone therapy is effective for the long-term treatment of patients with such tachycardia. In patients with Wolff-Parkinson-White syndrome, intravenous propafenone therapy is effective for both terminating the reentrant tachycardia and controlling the ventricular rate during atrial fibrillation. The drug seems to be well tolerated, and no significant adverse hemodynamic effects are noted when the drug is given intravenously.
